DA 7503
Alternative Names: DA-7503Latest Information Update: 05 Jun 2026
At a glance
- Originator Dong-A ST
- Class Antidementias; Small molecules
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease; Tauopathies
Most Recent Events
- 12 Jan 2026 Dong-A ST completes a phase I trial in Alzheimer's disease (In volunteers) and Tauopathies (In volunteers) in South Korea (PO) (NCT06391827)
- 27 Jul 2025 Pharmacodynamics and adverse events data from preclinical trials in Alzheimer's disease presented at Alzheimer's Association International Conference 2025 (AAIC-2025)
- 28 Jul 2024 Pharmacodynamics data from a preclinical trial in Alzheimer's disease and Tauopathies presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)